Movatterモバイル変換


[0]ホーム

URL:


Journal Logo

Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.

Export to

Review Paper: PDF Only

Cancer procoagulant

a factor X activator, tumor marker and growth factor from malignant tissue

Gordon, S. G.; Mielicki, W. P.

Author Information

S. G. Gordon is with the Department of Pathology, B-169, University of Colorado Health Sciences Center and the University of Colorado Cancer Center, 4200 East 9th Avenue, Denver, CO 80262, USA, and W. P. Mielicki is with the Medical University of Lodz, Department of Biochemistry, Institute of Environmental Research and Bioanalysis, 90151 Lodz, Muszynskiego 1, Poland. Address correspondence to: S. G. Gordon, University of Colorado Health Sciences Center, Department of Pathology, Campus Box B216, 4200 East Ninth Avenue, Denver, CO 80262, USA. Tel: +(1) 303 315 8987; Fax: +(1) 303 315 4792; Email:stu.gordon#uchs.edu.

Blood Coagulation & Fibrinolysis8(2):p 73-86, March 1997.

Abstract

Hemostatic abnormalities associated with malignant disease led to the search for and discovery of a proteolytic enzyme that activated factor X in the blood coagulation cascade. It was named cancer procoagulant (CP). CP is a cysteine proteinase that is found in malignant and fetal (human amnion-chorion) tissue; it has not been found in normally differentiated tissue. It is a calcium-dependent, Mn2+ stimulated enzyme that has enhanced activity and inhibition in a reduced environment. This review presents a complete compilation and discussion of the known chemical and enzymatic characteristics of CP as well as many purification and assay procedures. Several unique properties of these procedures are described. Some problems and controversies are highlighted in each of the sections. An immunoassay for CP as a tumor marker and some of its potential applications in the diagnosis and monitoring of cancer are reviewed. Some therapeutic implications of CP are noted in light of the observation that antibodies to CP block the metastatic seeding of lung coloniesin vivo and diminish the viability of tumor cellsin vitro. Finally, comments about the relationship between tissue factor and CP in the malignant cells are provided.

© Lippincott-Raven Publishers.

You can read the full text of this article if you:

Log InAccess through Ovid
Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.


[8]ページ先頭

©2009-2026 Movatter.jp